Analysts expect Agios Pharmaceuticals, Inc. to report revenue of 49.13 M for Q3 26, against a range of 46.84 M to 51.42 M. The most recent reported quarter, Q2 26, came in at 44.74 M, a 60.6% beat against the 27.86 M consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 9.00 M | 10.70 M | 8.70 M | 12.50 M | 12.90 M | 19.97 M | 20.75 M | 44.74 M | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 10.58 M | 9.15 M | 9.75 M | 10.54 M | 11.47 M | 12.45 M | 14.38 M | 29.82 M | 51.42 M | 69.15 M | 76.29 M | 91.50 M | 91.73 M | 106.32 M | 99.09 M | 107.52 M | ||||||||||
| Low Estimate | 9.20 M | 8.59 M | 8.65 M | 9.73 M | 10.78 M | 10.43 M | 12.97 M | 25.89 M | 46.84 M | 57.59 M | 65.45 M | 85.06 M | 78.26 M | 92.90 M | 83.28 M | 90.67 M | ||||||||||
| Consensus Estimate | 9.89 M | 8.87 M | 9.20 M | 10.14 M | 11.12 M | 11.44 M | 13.67 M | 27.86 M | 49.13 M | 63.37 M | 70.87 M | 88.28 M | 85.00 M | 99.61 M | 91.18 M | 99.10 M |
Analysts expect Agios Pharmaceuticals, Inc. to report earnings per share of -1.17 for Q3 26, against a range of -1.27 to -1.07. The most recent reported quarter, Q2 26, came in at -1.69, a 6.3% miss against the -1.59 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 16.22 | -1.44 | -1.55 | -1.93 | -1.78 | -1.86 | -1.69 | -1.69 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 16.60 | -1.49 | -1.55 | -1.62 | -1.79 | -1.96 | -1.54 | -1.44 | -1.07 | -1.16 | -0.95 | -0.80 | -2.27 | -3.76 | 0.84 | 1.63 | ||||||||||
| Low Estimate | 15.30 | -1.73 | -1.75 | -1.90 | -2.17 | -2.16 | -1.86 | -1.74 | -1.27 | -1.26 | -1.05 | -0.92 | -2.77 | -4.36 | 0.74 | 1.49 | ||||||||||
| Consensus Estimate | 15.95 | -1.61 | -1.65 | -1.76 | -1.98 | -2.06 | -1.70 | -1.59 | -1.17 | -1.21 | -1.00 | -0.86 | -2.52 | -4.06 | 0.79 | 1.56 |
Pull Wall Street consensus for Agios Pharmaceuticals, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=AGIO&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "AGIO", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=AGIO&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();